Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
तुलना करने के लिए मीट्रिक्स | XLO | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधXLOपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.7x | −7.3x | −0.4x | |
PEG अनुपात | −0.03 | 0.01 | 0.00 | |
क़ीमत/बुक | −4.8x | 2.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.2x | 7.7x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 264.1% | 70.8% | 58.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.7% | 9.2% | अनलॉक करें |